Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is used for the treatment of (paediatric) hypertension, heart failure and chronic kidney diseases. Because its disposition, efficacy and safety differs across the paediatric continuum, data from adults cannot be automatically extrapolated to children. This review highlights paediatric enalapril pharmacokinetic data and demonstrates that these are inadequate to support with certainty an age-related effect on enalapril/enalaprilat pharmacokinetics. In addition, our review shows that evidence to support effective and safe prescribing of enalapril in children is limited, especially in young children and heart failure patients; studies in these groups are either absent or show conflicting results. We provide explanations for observed differences between age groups and indications, and describe areas for future research.

依那普利是一种血管紧张素转换酶 (ACE) 抑制剂，用于治疗（儿童）高血压、心力衰竭和慢性肾脏疾病。由于其处置、功效和安全性在整个儿科连续体中有所不同，因此成人的数据不能自动推断到儿童。本综述重点介绍了儿科依那普利药代动力学数据，并表明这些数据不足以肯定地支持年龄相关的依那普利/依那普利拉药代动力学影响。此外，我们的综述表明，支持对儿童（尤其是幼儿和心力衰竭患者）有效且安全地开依那普利处方的证据有限；对这些群体的研究要么缺乏，要么显示出相互矛盾的结果。我们对年龄组和适应症之间观察到的差异提供了解释，并描述了未来研究的领域。